

Neuroprotective Agents in Cerebral Malaria

PROJECT DESCRIPTION

Malaria is a leading killer globally, claiming an estimated 429,000 lives annually. New adjunctive agents are urgently needed to improve outcomes in children with cerebral malaria, a severe neurological complication of *Plasmodium falciparum* infection. We are studying two target pathways that may be targeted by novel pharmacologic agents to stabilize the blood brain barrier and improve outcomes in cerebral malaria: sphingosine-1 phosphate and vascular endothelial growth factor. Techniques include cell culture, flow cytometry, ELISA, and others. The student will learn transferable lab skills and work on a "translational" research project, with potential to improve outcomes in a disease of global health importance.

FACULTY-DEPARTMENT

Medicine - Pediatrics

DESIRED FIELD OF (STUDENT) STUDY

Biological sciences, with lab experience

INTERNSHIP LOCATION

University of Alberta Main Campus - Edmonton

NUMBER OF INTERNSHIP POSITIONS

1

INTERNSHIP START DATE

July 4, 2018

INTERNSHIP END DATE

October 4, 2018

ARE THE DATES FLEXIBLE?

Yes, I am flexible regarding the internship dates. Selected students can contact me to request a date change.

Contact: Brendan Cavanagh, Internship Coordinator (Inbound)
University of Alberta International
intern@ualberta.ca